Novus Therapeutics (NASDAQ: NVUS) and Motif (NASDAQ:MTFB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.
Institutional & Insider Ownership
39.9% of Novus Therapeutics shares are held by institutional investors. Comparatively, 7.4% of Motif shares are held by institutional investors. 4.3% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent recommendations for Novus Therapeutics and Motif, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Novus Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 16.67%. Motif has a consensus price target of $19.50, suggesting a potential upside of 127.54%. Given Motif’s higher probable upside, analysts plainly believe Motif is more favorable than Novus Therapeutics.
Valuation and Earnings
This table compares Novus Therapeutics and Motif’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Novus Therapeutics||N/A||N/A||-$13.11 million||N/A||N/A|
Volatility & Risk
Novus Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Motif has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500.
This table compares Novus Therapeutics and Motif’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Novus Therapeutics beats Motif on 5 of the 9 factors compared between the two stocks.
Novus Therapeutics Company Profile
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Motif Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.